Denmark Tackles ‘All Talk And No Action’ On Decentralized Clinical Trials
EU Allows Expanded Use Of Remote Source Data Verification
Executive Summary
Danish regulators tell the Pink Sheet they want to know what is holding companies back from submitting applications for decentralized clinical trials and are keen to find creative solutions to possible hurdles.
You may also be interested in...
Decentralized Clinical Trials ‘No Longer A Leap Of Faith’
This second segment of a two-part Pink Sheet article on decentralized clinical trials looks at ensuring that staff at study sites are on onboard to support fast-paced change in this field, how regulatory guidance can help tackle hesitancy, and the need to transparently track such studies.
Are Trial Sponsors Treading On Investigators’ Toes In Decentralized Trials?
The Danish regulator’s experience with reviewing and inspecting decentralized elements in clinical trials highlights concerns around the blurring of lines that divide the roles and responsibilities of sponsors and trial investigators.
EU Decentralized Trials Guide Due Early In 2022
The upcoming EU guideline on decentralized clinical trials is the result of a “learning by doing” exercise and builds on various pilots and initiatives launched by different member states.